ArticleGastroenterology2008
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.
Article in Gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.The American journal of gastroenterology · 2011Pooled it
- Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Review
- Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Recurring Translocations in Barrett's Esophageal Adenocarcinoma.Frontiers in genetics · 2021Article
- Buried Barrett's Esophagus with High-Grade Dysplasia after Radiofrequency Ablation.Clinical endoscopy · 2019Article
- Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.Cancers · 2017Review
- Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.United European gastroenterology journal · 2017Article
- Post-ablation surveillance in Barrett's esophagus: A review of the literature.World journal of gastroenterology · 2016Review
- Barrett's esophagus in 2016: From pathophysiology to treatment.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers.Gastrointestinal endoscopy · 2014Article
- Sixteen-year follow-up of Barrett's esophagus, endoscopically treated with argon plasma coagulation.United European gastroenterology journal · 2014Article
- Histopathology in barrett esophagus and barrett esophagus-related dysplasia.Clinical endoscopy · 2014Review
- Predictive biomarkers for Barrett's esophagus: so near and yet so far.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2013Review
- Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma.Gastroenterology clinics of North America · 2013Review
- GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?Gastroenterology research and practice · 2013Article
- Biomodulatory approaches to photodynamic therapy for solid tumors.Cancer letters · 2012Review
- Buried (but not dead) Barrett's metaplasia: tales from the crypts.Gastrointestinal endoscopy · 2012Article
- Safety of prior endoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett's esophagus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2012Article
- Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.PLoS genetics · 2011Article
- Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?World journal of gastroenterology · 2010Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND &
aimsPhotodynamic therapy (PDT) has been shown to be effective in the treatment of high-grade dysplasia (HGD)/mucosal carcinoma in Barrett's esophagus (BE). Substantial proportions of patients do not respond to PDT or progress to carcinoma despite PDT. The role of biomarkers in predicting response to PDT is unknown. We aimed to determine if biomarkers known to be associated with neoplasia in BE can predict loss of dysplasia in patients treated with ablative therapy for HGD/intramucosal cancer.
methodsPatients with BE and HGD/intramucosal cancer were studied prospectively from 2002 to 2006. Biomarkers were assessed using fluorescence in situ hybridization performed on cytology specimens, for region-specific and centromeric probes. Patients were treated with PDT using cylindric diffusing fibers (wavelength, 630 nm; energy, 200 J/cm fiber). Univariate and multiple variable logistic regression was performed to determine predictors of response to PDT.
resultsA total of 126 consecutive patients (71 who underwent PDT and 55 patients who did not undergo PDT and were under surveillance, to adjust for the natural history of HGD), were included in this study. Fifty (40%) patients were responders (no dysplasia or carcinoma) at 3 months after PDT. On multiple variable analysis, P16 allelic loss (odds ratio [OR], 0.32; 95% confidence interval [CI], 0.10-0.96) predicted decreased response to PDT. BE segment length (OR, 0.71; 95% CI, 0.59-0.85), and performance of PDT (OR, 7.17; 95% CI, 2.50-20.53) were other independent predictors of loss of dysplasia.
conclusionsp16 loss detected by fluorescence in situ hybridization can help predict loss of dysplasia in patients with BE and HGD/mucosal cancer. Biomarkers may help in the selection of appropriate therapy for patients and improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.